Background: Current inhaled polymyxin therapy is empirical and often large doses are administered, which can lead to pulmonary adverse effects. There is a dearth of information on the mechanisms of polymyxin-induced lung toxicity and their intracellular localization in lung epithelial cells.
Introduction
The world is facing a major challenge due to the prevalence of MDR Gram-negative bacteria, particularly Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae. [1] [2] [3] In the last two decades, the situation has become worse due to the lack of novel classes of antibiotics in the developmental pipeline. 4 Polymyxins have been reinvigorated as a last-line therapy against these Gram-negative 'superbugs'. 5 Parenteral polymyxin therapy is associated with a high incidence (up to 60%) of nephrotoxicity in patients. [6] [7] [8] Moreover, current dosing recommendations for parenteral polymyxins are suboptimal, in particular for lung infections, because of the very limited distribution of polymyxins into the infection site. [9] [10] [11] [12] [13] [14] Inhaled colistin (in the form of an inactive prodrug, colistimethate) has been widely used in European cystic fibrosis centres over the last three decades for the treatment of lung infections caused by P. aeruginosa. [15] [16] [17] [18] Dose fractionation studies of aerosolized polymyxin B and colistin in animals showed a significant reduction in the bacterial load as well as pulmonary inflammation. 19, 20 However, inhaled polymyxin therapy has never been optimized in patients using pharmacokinetics/pharmacodynamics (PK/PD), which has potentially led to a number of adverse effects. [21] [22] [23] [24] Clearly, there is an urgent need to address this issue and elucidate the mechanism underlying polymyxininduced pulmonary toxicity.
We have recently demonstrated that polymyxin B can cause time-and concentration-dependent toxicity in lung epithelial cells via extrinsic and intrinsic pathways of apoptosis. 25 Interestingly, polymyxins are more toxic to human renal tubular HK-2 cells, compared with human lung epithelial A549 cells, with significantly higher intracellular concentrations. 25 Our synchrotron X-ray fluorescence microscopy data showed that polymyxins accumulate in rat (NRK-52E) and human (HK-2) kidney tubular cells at levels 1930-4760-fold higher than the extracellular concentrations. 26 Partial co-localization of polymyxins with mitochondria was associated with nephrotoxicity in both cell culture and animal models. [26] [27] [28] Significant morphological changes of mitochondria from filamentous to fragmented were also reported in NRK-52E cells after polymyxin treatment. 29 To date, no information is available on the intracellular disposition of polymyxins in lung epithelial cells. The aim of this study was to investigate the intracellular localization of polymyxins in human lung epithelial cells.
Materials and methods

Materials
Polymyxin B (sulphate; catalogue number 86-40302; minimum potency, 95%) and colistin (sulphate; catalogue number 86-41620; minimum potency, 95%) were purchased from Beta Pharma (Shanghai, China). Pierce TM methanol-free 16% formaldehyde (w/v, catalogue number 28908) was from Thermo Fisher Scientific and a 3.7% working solution was prepared. Permeabilizing solution (Triton X-100 solution, catalogue number T9284) and blocking reagents (goat serum, catalogue number G9023) were purchased from Sigma-Aldrich (Melbourne, Australia Effect of polymyxin treatment on the cellular protein degradation pathway
The two major pathways of selective cellular protein degradation were examined. Firstly, the ubiquitin-proteasome pathway was assessed by staining ubiquitin with rabbit polyclonal anti-ubiquitin antibody (Abcam, catalogue number ab7780; 1:500) after polymyxin B treatment (0.1 mM for 24 h). Co-localization of polymyxin B with expressed ubiquitin was studied by confocal imaging using a Leica SP8 inverted microscope. Secondly, the lysosome was assessed by staining lysosome-associated membrane protein (LAMP-1) with rabbit polyclonal anti-LAMP-1 (1:500). Co-localization was validated by analysing the image for the overlapping intensity of two different channels using the Coloc 2 plugin (ImageJ 1.51n, NIH, USA). The concentration-dependent effect of polymyxin B treatment (0.1, 0.5 and 1.0 mM for 24 h) on the lysosomal activity was evaluated by calculating the intensity of LysoTracker TM deep red (Life Technologies, catalogue number L12492) in live cells. One-way analysis of variance (ANOVA) was conducted for significance testing using GraphPad prism (Version 7.01, CA, USA).
Co-localization of polymyxin B with autophagic protein LC3A
A549 cells were treated with 0.1, 0.5 and 1.0 mM polymyxin B for 24 h. Cells were then washed with PBS followed by fixation (4% paraformaldehyde for 15 min) and permeabilization (0.1% Triton X-100 for 10 min). Cells were blocked with 1% goat serum for 2 h and incubated overnight with rabbit anti-LC3A monoclonal antibody (1:100) in a dark chamber at 4 C. After overnight incubation with the primary antibody, cells were incubated with the goat anti-rabbit secondary antibody conjugated with Alexa V R Fluor 488 (1:500). Cells were then imaged with a Leica SP8 (inverted) confocal microscope using a 63% oil immersion objective [numerical aperture (NA) 1.4]. The concentration-dependent effect of polymyxin B on autophagic protein expression was also assessed. Immunofluorescence was measured from three independent fields of each individual sample. The background was subtracted and the fluorescence intensity per cell was calculated.
Mitochondrial localization of polymyxins and changes in the mitochondrial morphology
Mitochondria were stained with rabbit polyclonal anti-TOMM20 antibody (1:500). After overnight incubation with the primary antibody at 4 C, all samples were stained with goat anti-rabbit IgG conjugated with Alexa V R Fluor 488 (1:500) for 2 h at room temperature. Hoechst 33342 (Life Technologies, catalogue number H3570, 2 lg/mL) was used as a nuclear stain. Mitochondria and polymyxin B channel intensities were used for 3D visualization of polymyxin B co-localized with mitochondria. Images were collected from multiple Z-stacks of a cell and a 3D overlap of two channel intensities was created using the Imaris platform. To assess the mitochondrial morphology, cells were treated with 0.1 and 1.0 mM polymyxin B for 1, Intracellular localization of polymyxins JAC 4 and 24 h, washed with PBS and treated with 100 nM tetramethylrhodamine, ethyl ester (TMRE) for 45 min to stain the mitochondria. Cells were visualized under a Leica SP8 confocal microscope to identify filamentous (branched) and fragmented mitochondria in TMRE-stained viable cells. Mitochondrial morphologies were categorized into 'filamentous' (for long, elongated and branched networks), 'fragmented' (for short networks and small spheres) and 'intermediates' (for a mixture of networks and fragments). 29, 30 More than 200 cells were counted for each treatment condition and the experiments were repeated three times. NIH ImageJ software was used to count the cells with filamentous/fragmented/intermediate mitochondria. Polymyxin B-induced mitochondrial morphology changes were determined by counting the number of cells with different mitochondrial morphologies and expressed as a percentage of the total cell count. 31 
Imaging and image analysis
All images were representative of several cells from three separate experiments. Vehicle-treated cells were employed as the control. Background intensity of the control was subtracted from treatment groups. Coloc 2 was used to perform the pixel intensity correlation for image analysis, automatic thresholding and statistical testing. The Imaris platform was used to process the two channel intensities simultaneously and to measure the degree of overlap of the two channels. The optics of the microscope were adjusted to prevent any potential crosstalk of signals between different channels. Images were verified by collecting images of single fluorescently labelled samples with the same settings used for co-localization studies. Finally, optical sectioning was employed to capture the images of multiple sections of cells and an image of the entire 3D volume of the cells was created.
Results
Significant co-localization of polymyxin B with early endosomes (Pearson's R " 0.70) was observed, whereas co-localization with late endosomes was not significant (Pearson's R " 0.10) (Figure 1a and b). Polymyxin B was also significantly co-localized with ubiquitin (Pearson's R " 0.39, Figure 2 ) and lysosomes (Pearson's R " 0.17, Figure 3) . A significant increase in the lysosomal activity (measured by LysoTracker TM deep red intensity per cell) was observed in A549 cells treated with 0.5 mM (**P , 0.05) and 1.0 mM (***P , 0.001) polymyxin B for 24 h. Co-localization of polymyxin B with autophagic protein LC3A was not detected; however, an increased formation of autophagic vesicles was evident in A549 cells following 0.5 and 1.0 mM polymyxin B treatment for 24 h (Figure 4 ). LC3A intensity in the cells treated with 0.1 mM polymyxin B was unchanged, compared with the control. Significant increase in the LC3A intensity was observed with 0.5 mM (**P , 0.05) and 1.0 mM (****P , 0.0001) polymyxin B treatment for 24 h.
Polymyxin B co-localized with mitochondria in A549 cells (Figure 5a ) and confocal images showed significant accumulation of polymyxin B on mitochondria at all three timepoints (1, 4 and 24 h). The 3D visualization indicated significant co-localization of polymyxin B with mitochondria ( Figure 5b) . A 3D demonstration of mitochondrial distribution in the cells without polymyxin B treatment is presented in Figure S1 (available as Supplementary data at JAC Online). Polymyxin B treatment induced significant changes in the mitochondrial Ahmed et al.
morphology in A549 cells (Figure 6a) . A significant number of cells with both filamentous and fragmented mitochondria at 24 h were observed after treatment with 0.1 mM polymyxin B, compared with the control (Figure 6b) . A concentration-and time-dependent increase in the number of cells with fragmented mitochondria (short and disjointed) was evident; the most significant increase (****P , 0.0001) in the cells with fragmented mitochondria (40.8+11.5%) was observed at 24 h following 1.0 mM polymyxin B treatment (Figure 6c ). 
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Discussion
Over the last few decades, inhaled polymyxins (most commonly as colistimethate) have shown favourable efficacy against Gramnegative pathogens in lung infections. [32] [33] [34] [35] [36] Pulmonary delivery of polymyxins has the advantage of achieving significant high concentrations in the epithelial lining fluid. 19, 20 Considering PK/PD/toxicodynamics (PK/PD/TD), extensive accumulation of polymyxins in lung epithelial cells may potentially cause pulmonary toxicity. [21] [22] [23] [24] We have previously reported that polymyxin-induced toxicity in human lung epithelial A549 cells involves apoptosis and mitochondrial dysfunction. 25 The present study examined the intracellular localization of polymyxins in lung epithelial cells and provides key insights into the mechanism of polymyxin-induced pulmonary toxicity.
Endocytosis is a major route of cellular drug internalization and endocytosed molecules are initially delivered to small and irregularly shaped early endosomes. 37 Localization of polymyxins with early endosomes indicated a major route of polymyxin internalization in A549 cells (Figure 1 ). Rab proteins are critical regulators of endocytosis. 38 In our study significant localization of polymyxin B was found only with the early endosome marker Rab5, but not the late endosome marker Rab7 (Pearson's R " 0.10). This indicates that polymyxin B molecules might bind to the extracellular domain of the receptor and were subsequently internalized by receptor-mediated endocytosis. 39, 40 Proteasomes and lysosomes are two major protein degradation pathways in eukaryotic cells. 41 Ubiquitin is a 76 amino acid polypeptide and is used by proteasomes as a marker to target cytosolic and nuclear proteins for rapid degradation, whereas lysosomes are mostly involved in the digestion of extracellular proteins taken up by endocytosis as well as cytosolic proteins. 42 Proteins are marked by ubiquitin attached to the amino group of the side chain of a lysine residue and degraded afterwards. Polymyxins are Intracellular localization of polymyxins JAC rich in 2,4-diaminobutyric acid (Dab) residues, which are structurally similar to lysine residues. 43 The intracellular co-localization of polymyxin B with ubiquitin indicated that A549 cells might tag the polymyxin molecule with ubiquitin for rapid degradation (Figure 2) , which might play a significant role in cellular defence mechanisms, as well as polymyxin metabolism.
Lysosomes are membrane-enclosed compartments filled with 40 types of hydrolytic enzymes (e.g. glycosidases, lipases, nucleases, phospholipases, phosphatases, proteases and sulphatases) which are used to control the intracellular digestion of macromolecules. 44 Polymyxin B was also co-localized with lysosomes and caused a concentration-dependent increase in the lysosomal activity (Figure 3) . LysoTracker TM deep red is a pH-dependent dye; the lysosomal pH reduced (more acidic) as polymyxin B concentration in lysosomes increased (Figure 3 ). Lysosomal drug sequestration plays an important role in the acquired resistance to doxorubicin in MCF-7 breast tumour cells. 45 Co-localization of polymyxins with lysosomes and ubiquitin may indicate the degradation of polymyxins in lung epithelial cells and the subsequent lysosomal exocytosis. 46 Although polymyxin B was not co-localized with autophagosomes, a concentration-dependent increase of the autophagic protein LC3A was observed after treatment with 0.1, 0.5 and 1.0 mM polymyxin B at 24 h (Figure 4 ). Significant increase of LC3A in formed autophagosomes was evident at 24 h after 0.5 mM (**P , 0.05) and 1.0 mM (****P , 0.0001) polymyxin B treatment (Figure 4) . Autophagy is a self-degradative process to balance different sources of energy for cellular development and in response to stresses. 45 The formation of the autophagosome and lysosome is a cellular response to stress and they are destructive mechanisms to disassemble unnecessary or dysfunctional components. They also play a housekeeping role in removing misfolded proteins, damaged mitochondria, ER and peroxisomes. 47 Measured by an increase in LC3A intensity, treatment with high concentrations of polymyxin B (0.5 mM) induced a dose-dependent increase in the autophagy process in lung epithelial cells. In kidney tubular and neuron cells, it has been reported that polymyxin B induced an increase in autophagic protein LC3A in a concentrationdependent manner, indicating that polymyxins induced autophagic cell death in mammalian cells. 28, 48 Mitochondria are essential for the maintenance of cellular homeostasis and dysfunction leads to oxidative stress and cell death. 49 Polymyxins mainly co-localized with mitochondria in A549 and caused concentration-and time-dependent changes in the mitochondrial morphology (Figures 5 and 6 ). Mitochondrial morphology from networked to fragmented is regulated via mitochondrial fusion and fission processes in response to cellular stresses. 50 A tendency of losing mitochondrial membrane protein TOMM-20 was discovered with increased accumulation of polymyxins in A549 cells ( Figure S2 ). In our previous study, we demonstrated concentration-and timedependent effects of polymyxin B on decreased mitochondrial membrane potential, increased mitochondrial oxidative stress and increased caspase-9 activation in A549 cells. 25 Collectively, our findings demonstrated that polymyxin treatment caused mitochondrial toxicity (e.g. membrane depolarization, oxidative Ahmed et al.
stress and morphology) and triggered the mitochondrial apoptosis pathway in lung epithelial cells. 25 Polymyxins partially co-localized with ER in rat renal tubular cells and up-regulated several proteins involved in the ER pathway in murine nephrotoxicity models. 27, 28 However, no co-localization of polymyxins within ER was observed in lung epithelial cells ( Figure S3 ). This indicates that the intracellular localization of polymyxins is different in different types of cells, and in A549 cells the ER pathway in polymyxin-induced toxicity may be secondary to mitochondrial dysfunction. 51 Like polymyxin B, colistin also colocalized with ubiquitin and lysosomes and mitochondria ( Figures  S4 and S5 ), which indicates both lipopeptides share similar intracellular targets for toxicity and might have similar effects on the protein degradation pathways. Polymyxins also activate the death receptor pathway of apoptosis by increasing FasL expression and caspase-8 activation in both lung and kidney epithelial cells. 25, 29 The polymyxin-induced interplay between different cellular trafficking and apoptosis pathways is still not clear and requires further investigation. Nevertheless, based upon our findings and the literature, we proposed putative cellular trafficking and potential toxicity pathways due to polymyxin treatment in lung epithelial cells (Figure 7) . Polymyxins may bind to the extracellular domain of the endocytic receptor megalin (MR) and be internalized via early endosomes. [52] [53] [54] [55] Oligopeptide transporter 2 (PEPT2) may play a significant role in the uptake of polymyxins. 56, 57 Mitochondrial toxicity and an increase in autophagy may play a significant role in polymyxin-induced apoptosis and cell death. 25, 58, 59 To the best of our knowledge, this study is the first to reveal the intracellular localization and trafficking of polymyxins in lung epithelial cells and provides key mechanistic information for optimization of inhaled polymyxins in patients. PK/PD approaches are required to decrease the exposure and apoptotic effect of polymyxins in lung epithelial cells, thereby minimizing their potential pulmonary toxicity and widening the therapeutic window of polymyxin inhalation therapy. 
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